Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 209239, held by Glenmark Speclt. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 209239 (Solifenacin Succinate), held by Glenmark Speclt, was first approved by FDA on May 20, 2019, with 1 approved supplement and 0 published complete response letters.
Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
| Nov 24, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters